ATE536913T1 - Verwendung eines ppar-alpha agonists zur behandlung von mit ppar-gamma agonist-behandlung assozierten körpergewichtszunahme - Google Patents

Verwendung eines ppar-alpha agonists zur behandlung von mit ppar-gamma agonist-behandlung assozierten körpergewichtszunahme

Info

Publication number
ATE536913T1
ATE536913T1 AT03792272T AT03792272T ATE536913T1 AT E536913 T1 ATE536913 T1 AT E536913T1 AT 03792272 T AT03792272 T AT 03792272T AT 03792272 T AT03792272 T AT 03792272T AT E536913 T1 ATE536913 T1 AT E536913T1
Authority
AT
Austria
Prior art keywords
ppar
agonist
weight gain
body weight
gain associated
Prior art date
Application number
AT03792272T
Other languages
English (en)
Inventor
Jean-Louis Junien
Alan Edgar
Evelyne Chaput
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02291994A external-priority patent/EP1388351A1/de
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Application granted granted Critical
Publication of ATE536913T1 publication Critical patent/ATE536913T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03792272T 2002-08-08 2003-08-06 Verwendung eines ppar-alpha agonists zur behandlung von mit ppar-gamma agonist-behandlung assozierten körpergewichtszunahme ATE536913T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02291994A EP1388351A1 (de) 2002-08-08 2002-08-08 Verwendung eines Fibrats zur Behandlung von rosiglitazon-assozierter Fettleibigkeit
EP02292830A EP1388352A1 (de) 2002-08-08 2002-11-14 Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
PCT/EP2003/008756 WO2004018041A1 (en) 2002-08-08 2003-08-06 Use of a ppar-alpha agonist to treat weight gain associated with a ppar-gamma agonist treatment

Publications (1)

Publication Number Publication Date
ATE536913T1 true ATE536913T1 (de) 2011-12-15

Family

ID=30445152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792272T ATE536913T1 (de) 2002-08-08 2003-08-06 Verwendung eines ppar-alpha agonists zur behandlung von mit ppar-gamma agonist-behandlung assozierten körpergewichtszunahme

Country Status (10)

Country Link
US (2) US20040110799A1 (de)
EP (2) EP1388352A1 (de)
JP (1) JP4588448B2 (de)
CN (1) CN1674959A (de)
AT (1) ATE536913T1 (de)
AU (1) AU2003260380B2 (de)
CA (1) CA2493747A1 (de)
ES (1) ES2379165T3 (de)
NO (1) NO20050526L (de)
WO (1) WO2004018041A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
WO1991006677A1 (en) 1989-10-25 1991-05-16 The Salk Institute For Biological Studies Receptor infection assay
AU637446B2 (en) 1990-01-16 1993-05-27 Baylor College Of Medicine Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
CA2090407A1 (en) 1990-09-21 1992-03-22 Ronald M. Evans Functional antagonism between proto-oncoprotein c-jun and hormone receptors
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
WO1993011235A1 (en) 1991-12-06 1993-06-10 The Salk Institute For Biological Studies Multimeric forms of members of the steroid/thyroid superfamily of receptors
CA2135644C (en) 1992-05-14 2009-01-27 Elisabetta Vegeto Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
WO1994023068A1 (en) 1993-04-07 1994-10-13 Ligand Pharmaceuticals, Incorporated Method for screening for receptor agonists
US5506102A (en) 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
CA2180271A1 (en) 1993-12-30 1995-07-06 Ronald M. Evans Novel uses for gal4-receptor constructs
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
ES2217392T3 (es) 1996-02-02 2004-11-01 MERCK & CO., INC. Agentes antidiabeticos.
AU712607B2 (en) 1996-02-02 1999-11-11 Merck & Co., Inc. Method of treating diabetes and related disease states
AU708055B2 (en) 1996-02-02 1999-07-29 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
CA2245529A1 (en) 1996-02-02 1997-08-07 Soumya P. Sahoo Antidiabetic agents
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
TW438784B (en) 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
DE69929996T2 (de) * 1998-06-30 2006-11-16 Takeda Pharmaceutical Co. Ltd. Pharmazeutisches mittel zur behandlung von diabetes
US20040009961A1 (en) 2000-04-19 2004-01-15 Borody Thomas Julius Composition and therapies for hyperlipidaemia-associated disorders
ATE362468T1 (de) * 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
AU2001255515A1 (en) * 2000-09-20 2002-04-02 Skyepharma Canada Inc. Stabilised fibrate microparticles
WO2002028857A1 (en) * 2000-10-05 2002-04-11 Dr. Reddy's Research Foundation Polymorphs of pioglitazone hydrochloride and their use as antidiabetics
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators

Also Published As

Publication number Publication date
JP2005539033A (ja) 2005-12-22
US20090099238A1 (en) 2009-04-16
CN1674959A (zh) 2005-09-28
WO2004018041A1 (en) 2004-03-04
EP1388352A1 (de) 2004-02-11
EP1526894A1 (de) 2005-05-04
AU2003260380B2 (en) 2008-11-06
NO20050526L (no) 2005-03-02
AU2003260380A1 (en) 2004-03-11
CA2493747A1 (en) 2004-03-04
JP4588448B2 (ja) 2010-12-01
ES2379165T3 (es) 2012-04-23
US20040110799A1 (en) 2004-06-10
EP1526894B1 (de) 2011-12-14

Similar Documents

Publication Publication Date Title
ATE427762T1 (de) Vorlage zur behandlung von hamorrhoiden
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
DE60026146D1 (de) Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction
EA200100084A1 (ru) Лекарственное средство, обладающее антидепрессивным действием
ATE174785T1 (de) Behandlung von akne oder von folliculitis barbae
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE504600T1 (de) Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
DE60314730D1 (de) Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
ATE472329T1 (de) Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE447426T1 (de) Elektromagnetische stimulation bei patienten mit osteoporose
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE536913T1 (de) Verwendung eines ppar-alpha agonists zur behandlung von mit ppar-gamma agonist-behandlung assozierten körpergewichtszunahme
DE69918145D1 (de) Verwendung von diltiazem zur behandlung von pathologien der netzhaut
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen